Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)
China flag China · Delayed Price · Currency is CNY
9.83
-0.06 (-0.61%)
Sep 4, 2026, 3:04 PM CST

SHE:002399 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
5,1895,3805,1865,4317,0976,318
Other Revenue
51.7598.9194.98-61.9247.33
5,2415,4795,2815,4317,1596,365
Revenue Growth
-0.37%3.75%-2.77%-24.14%12.48%19.38%
Cost of Revenue
3,4823,7733,5324,4904,8614,367
Gross Profit
1,7591,7061,749940.92,2981,998
Selling, General & Admin
916.64847.8786.751,192975.69850.68
Research & Development
205.77226.16212.04-252.14221.1
Other Operating Expenses
37.0147.2924.6-34.4922.7320.96
Operating Expenses
1,1711,1391,0161,1581,2991,165
Operating Income
587.9567.25732.91-217.29998.55833.53
Interest Expense
-22.52-71.44-141.18-223.22-235.24-201.63
Interest & Investment Income
30.6138.27240.3175.9554.1454.86
Earnings From Equity Investments
----447.95--
Currency Exchange Gain (Loss)
-73.94140.6-12.8485.87186.33-205.04
Other Non Operating Income (Expenses)
-253.57-70.18-77.96-30.71-32.55-46.18
EBT Excluding Unusual Items
268.48604.5741.23-757.34971.23435.53
Impairment of Goodwill
----68.16--
Gain (Loss) on Sale of Investments
-58.42-193.2445.6216.2-176.91-226.82
Gain (Loss) on Sale of Assets
-0.271.840.72--2.76-5.1
Asset Writedown
-16.95-19.31-55.52-44.52-0.42-1.1
Other Unusual Items
6.298.44-5.83-74.5238.7119.75
Pretax Income
199.13402.24726.23-928.33829.85222.26
Income Tax Expense
2.7759.6101.31-126.18114.82-11.12
Earnings From Continuing Operations
196.35342.64624.92-802.16715.04233.38
Minority Interest in Earnings
6.576.8521.8218.912.397.4
Net Income
202.92349.49646.74-783.26727.43240.79
Net Income to Common
202.92349.49646.74-783.26727.43240.79
Net Income Growth
-49.89%-45.96%--202.10%-76.49%
Shares Outstanding (Basic)
1,4671,4671,4671,4781,4681,467
Shares Outstanding (Diluted)
1,4671,4671,4671,4781,4681,467
Shares Change
0.01%--0.72%0.67%0.05%8.42%
EPS (Basic)
0.140.240.44-0.530.500.16
EPS (Diluted)
0.140.240.44-0.530.500.16
EPS Growth
-49.89%-45.96%--201.95%-78.32%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
1,3991,5921,991-39.22-979.03-200.49
Free Cash Flow Per Share
0.951.081.36-0.03-0.67-0.14
Dividend Per Share
0.1450.1450.250-0.1000.035
Dividend Growth
-42.00%-42.00%--185.71%-76.67%
Gross Margin
33.56%31.15%33.11%17.32%32.10%31.39%
Operating Margin
11.22%10.35%13.88%-4.00%13.95%13.10%
Profit Margin
3.87%6.38%12.25%-14.42%10.16%3.78%
Free Cash Flow Margin
26.70%29.05%37.71%-0.72%-13.68%-3.15%
EBITDA
921.61887.891,030105.611,2721,103
EBITDA Margin
17.58%16.20%19.51%1.94%17.77%17.34%
D&A For EBITDA
333.71320.64297.46322.89273.87269.92
EBIT
587.9567.25732.91-217.29998.55833.53
EBIT Margin
11.22%10.35%13.88%-4.00%13.95%13.10%
Effective Tax Rate
1.39%14.82%13.95%-13.84%-
Revenue as Reported
2,6625,4795,281-7,1596,365
Advertising Expenses
-25.926.18-23.218.04